G protein-coupled receptor kinase 3Genealiases: ADRBK2 · BARK2
Q-omics provides the consensus-scored GRK3 profile across patient tissues and cancer cell-line models. GRK3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, GRK3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GRK3 RNA expression shows 19,556 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, HNSC, and UVM as cancer lineages where GRK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRK3 survival associations across molecular data types. GRK3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRK3 RNA expression–survival associations across cancer types. High GRK3 expression shows unfavorable associations in UVM, but favorable associations in LGG, HNSC, BRCA, LUAD and BLCA. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for GRK3 RNA expression.
This table summarizes GRK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GRK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRK3 shows lower tumor expression in LUAD, BRCA and UCEC and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher GRK3 RNA expression in tumor versus normal tissue (log2 FC = +1.200, t-test p < 0.001).
This table shows molecular features associated with GRK3 in patient tissues and cancer cell lines. In patient samples, GRK3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
